RxDoctor Payments Data

Alice Ward, APRN

Nurse Practitioner · Pineville, KYNPI 1952693087

Payments from drug & device makers

$961in general payments, 2019–2025

Across 58 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$240
  • Johnson & Johnson$109
  • AstraZeneca$96
  • AbbVie$88
  • Lilly USA, LLC$82
  • Axsome Therapeutics, Inc.$62
  • plus $285 from 9 others

What the payments were for

  • Food & beverage$91295%
  • Education$495%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$961 in reported general payments places this provider in the 65th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,001
Medicare patients
49
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$93,465
JardianceEmpagliflozin69$58,975
TrulicityDulaglutide37$58,325
JanuviaSitagliptin Phosphate77$57,747
EliquisApixaban58$54,229
MounjaroTirzepatide19$19,389
Combivent RespimatIpratropium/Albuterol Sulfate14$10,181
LinzessLinaclotide13$9,968
Breo ElliptaFluticasone/Vilanterol16$9,315
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$8,712
MyrbetriqMirabegron13$8,452
EntrestoSacubitril/Valsartan13$8,224
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$7,579
Humalog Kwikpen U-100Insulin Lispro17$5,306
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$5,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$55$93,465104 claims
Lilly USA, LLCTrulicity, Mounjaro$82$77,71456 claims
Boehringer IngelheimJardiance, Combivent Respimat$12$69,15683 claims
MerckJanuvia, Dulera$39$62,88991 claims
PfizerEliquis$30$54,22958 claims
AbbVieLinzess, Synthroid$88$10,96224 claims
AstraZenecaSymbicort$96$3,83216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Pineville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →